Results 131 to 140 of about 5,337 (191)

Landscape of Apolipoprotein (APOE) in the Emirati Population and Recommendations for a Genotyping Approach for Amyloid-Beta Monoclonal Antibodies (Aβ-mAbs) in Alzheimer's Disease Patients. [PDF]

Cureus
Mohammed W, Al Ameri M, Al Marzooqi S, Alsafar H, Olbrich R, Mousa M, Barayan D, Magalhaes T, Quilez J, Reche J, Alkaf B, Shatila A, Marzouka NAD, Iqbal I, Yousif A, Rahma A, Al Mannaie A.   +16 more
europepmc   +1 more source

The highest clinical trial failure rate for any disease in modern medicine: How both amyloid- and non-amyloid-targeting therapies failed to alter disease course in Alzheimer's disease. [PDF]

Free Neuropathol
Guth MAS.
europepmc   +1 more source

Neuropathological changes and amyloid-related imaging abnormalities in Alzheimer's disease treated with aducanumab versus untreated: a retrospective case-control study. [PDF]

Lancet Neurol
Boon BDC, Piura YD, Moloney CM, Chalk JL, Lincoln SJ, Rutledge MH, Rothberg DM, Kouri N, Hinkle KM, Roemer SF, Johnson DR, Burkett BJ, Lowe VJ, Petersen RC, Dickson DW, Reichard RR, Nguyen AT, Graff-Radford J, Knopman DS, Graff-Radford NR, Murray ME.   +20 more
europepmc   +1 more source

Memory Consolidation and ARIA in Individuals Receiving Anti-amyloid Monoclonal Antibodies. [PDF]

J Prev Alzheimers Dis
Haut MW, Teixeira CVL, Worhunsky PD, Mehta RI, Malone JE, Ward M, Keith CM, Phelps HE, Pockl S, Rajabalee N, Sharif K, Marano G, D'Haese PF, Rezai AR.   +13 more
europepmc   +1 more source

Passive amyloid-β immunotherapy in Alzheimer's disease: a multicellular clearance system beyond plaque removal. [PDF]

Mol Neurodegener
Zhan X, Liu C, Yu C, Lindblom N, Deierborg T, Kobro-Flatmoen A, Gouras GK, Wen G.   +7 more
europepmc   +1 more source

Tau and β-Amyloid Relevant Pathology as a Central Therapeutic Target in Alzheimer's Disease. [PDF]

Biomolecules
Strużyńska L, Adamiak K, Sidoryk-Węgrzynowicz M.   +2 more
europepmc   +1 more source

Comparative effectiveness of multiple interventions for Alzheimer's disease on ABC syndromes and QoL: A Bayesian network meta-analysis. [PDF]

iScience
Gao F, Luo G, Liu B, Qiu X, Bai J, Wang R.   +5 more
europepmc   +1 more source

Transferrin receptor-binding blood-brain barrier shuttle enhances brain delivery and plaque-clearing efficacy of a therapeutic anti-Aβ antibody. [PDF]

Fluids Barriers CNS
Vega MR, Hansen HH, Jensen CS, Alexiou E, Madsen MR, Wichern F, Kristiansen MS, Skytte JL, Salinas CG, Sotty F, Jensen A, Vergo S, Hecksher-Sørensen J.   +12 more
europepmc   +1 more source

A review of evidence supporting amyloid beta reduction as a surrogate endpoint in Alzheimer's disease. [PDF]

J Prev Alzheimers Dis
Chen T, Hutchison RM, Rubel C, Murphy J, Xie J, O'Gorman J, Dent G, Molenberghs G, Sormani MP, Hendrix S, Hansson O, Aisen P, Haeberlein SB, Tian Y.   +13 more
europepmc   +1 more source

Data-driven modeling of amyloid-β targeted antibodies for Alzheimer's disease. [PDF]

NPJ Syst Biol Appl
Rabiei K, Petrella JR, Lenhart S, Liu C, Hao W, Alzheimer Disease Neuroimaging Initiative.   +5 more
europepmc   +1 more source